Allogene raises $120M in convertible notes

Just a few months after raising $300 million in a series A round, cell therapy company Allogene Therapeutics Inc. (South San Francisco, Calif.)

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE